Report a problem

28.6m / 27.6m

More Details..

	OR

Email Id:	(Required) (Required)
Password:	*(Required)
	Remember Me	Reset Password?
	Note: Please enter emailid to receive instructions to reset password.

	Not A Member Yet ? Sign Up

Email Id:	(Required) (Required)
Password:	*(Required)
	Remember Me	Reset Password?
	Note: Please enter emailid to receive instructions to reset password.

Name	*(Required)
Email	*(Required)
Telephone	(Required) (Invalid number !)
Subject	*(Required)
Comment	*(Required)


	Send

BANGARAIAH

Research Associate

Dion Global Solutions Limited

Bulls Eye

BANGARAIAH , Rashmi Sancheti

09 Nov 2015
BANGARAIAH , Carrol D'Silva , Deepak Tiwari, Dhruv Joshi, Gautam Mehta, Hardik , Hardik , Hiral Daiya, Hitesh Mahida, Kisan Ratilal, Meghna Luthra, Mehul Desai, Monica Gautam, Naveen Fernandes, Navin B. Agrawal, Nirvi , Palak Shah, Rashmi Sancheti

09 Nov 2015

BANGARAIAH

Linkedin:

Research Reports :

Dr Reddys Labs Target: Rs 4203.00
31 Jul 15

Dr Reddy's Labs..- ...

DRL’s Q1FY16 result was above our estimates on back of higher than expected operating performance. Revenues showed growth of 6.8% YoY to Rs. 3,758Crs.

KR Choksey

Indoco Remedies Target: Rs 403.00
31 Jul 15

Indoco Remedies Ltd...

Total revenues showed strong growth of 12.5% YoY to Rs 223crs in line with our estimates.

KR Choksey

Granules India Target: Rs 112.00
24 Jul 15

Granules India Ltd....

Total revenues showed growth of 11.2% YoY to Rs 346Crs in line with our estimates.

KR Choksey

Lupin Target: Rs 1780.00
24 Jul 15

Lupin Ltd. - Q1FY16...

EPS for the quarter stood at Rs 11.7.

KR Choksey

Unichem Labs Target: Rs 222.00
13 Jul 15

Unichem Labs. - Q1F...

Unichem’s result was above our expectation. Total revenues showed growth of 6.2% YoY & 20.7% QoQ to Rs 309crs on account of higher than expected growth in domestic business due to pick up in volume growth in chronic portfolio; however export formulation business posted modest growth of 11.6% YoY.

More..

KR Choksey

Cipla Target: Rs 704.00
30 May 15

Cipla Ltd.- Q4FY15 ...

Cipla’s Q4FY15 sales were in line but PAT misses estimates. Total income grew by 22.0% YoY to Rs. 3093crs mainly due to strong domestic & exports growth. EBITDA stood at Rs.508crs up by 24.0% YoY & down by 8.3% QoQ.

KR Choksey

Sun Pharma Target: Rs 991.00
30 May 15

Sun Pharma - Q4FY15...

Sun Pharma posted Q4FY15 & FY15 consolidated results after integration with Ranbaxy which were below our estimates on account of temporary supply constraints at its Halol plant, price erosion in large no. of products in US business of both Ranbaxy & Sun Pharma.

More..

KR Choksey

Indoco Remedies Target: Rs 405.00
28 May 15

Indoco Remedies Ltd...

Total revenues showed strong growth of 14.3% YoY to Rs 210crs on account of steady growth in domestic business which grew by 16.7% YoY.

KR Choksey

Dr Reddys Labs Target: Rs 3957.00
19 May 15

Company Update

We continue to maintain ‘ACCUMULATE’ rating with the revised target price of Rs. 3,957 at 22xFY17E.

KR Choksey

Cadila Pharmaceuticals Target: Rs 1904.00
16 May 15

Cadila Healthcare -...

Net sales grew by 17.3% YoY to Rs. 2247crs driven by improved traction in the US business.

KR Choksey

Lupin Target: Rs 1774.00
14 May 15

Lupin Ltd. - Q4FY15...

Lupin’s Q4FY15 results were below street & our estimates. Sales showed degrowth of 1.4% YoY to Rs3078crs on account of lower than expected US business mainly due to price erosion in some of its key products.

KR Choksey

Dr Reddys Labs Target: Rs 3957.00
13 May 15

Dr Reddy's Labs - Q...

DRL’s Q4FY15 revenues showed growth of 11.2% YoY to Rs. 3,870crs in line with our estimates mainly impacted by Russian market sales on account of Rouble depreciation.

KR Choksey

Unichem Labs Target: Rs 200.00
11 May 15

Unichem Labs. - Q4F...

Total revenues showed muted growth of 5.5% YoY to Rs 256crs on account of lower growth in domestic business impacted due to slow pick up in chronic portfolio; however export formulation business posted growth of 11% YoY.

KR Choksey

Granules India Target: Rs 112.00
29 Apr 15

Result Update

Total revenues showed growth of 11.7% YoY to Rs 355crs below our estimates. Auctus Pharma contributed around Rs 44.2crs to sales and made profit of 0.2crs at PBT level.

KR Choksey

Indoco Remedies Target: Rs 405.00
29 Apr 15

Initiating Coverage

Indoco Remedies is an Indian pharmaceuticals company with continuous focus on manufacturing and marketing of formulations & APIs. Indoco derives 61% of total sales from domestic formulations, 32% from exports and 7% from APIs.

KR Choksey